Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First-Line Ovarian Cancer Approval Solidifies Lead For AstraZeneca's Lynparza

Executive Summary

Lynparza will be the first PARP inhibitor cleared for maintenance treatment to extend response to first-line chemo, but in BRCA mutant patients – while Tesaro/GSK should have Phase III results for Zejula monotherapy in all-comers in 2019.

You may also be interested in...



Lynparza/Recentin Combo Fails In Phase III PSR Ovarian Cancer

Lynparza will weather the failure of the Phase III GY004 study, but VEGF inhibitor Recentin’s future looks even less certain; other studies of the combination continue.

New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza

Two new PARP inhibitor studiesGSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1  – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.

AZ Pushes Further Ahead In PARP Race With Lynparza/Avastin Combo

The PAOLA-1 study has shown the benefit of Lynparza for ovarian cancer patients regardless of tumor mutation status which should firm up the drug's dominance in the PARP inhibitor space.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel